Advances in nanotechnology for the management of coronary artery disease

Trends in Cardiovascular Medicine

Volumn 23, Issue 2, 2013, Pages 39-45

  Rhee, June Wha ^a   Wu, Joseph C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CCR2; CYTOKINE; FUMAGILLIN; GLUCOCORTICOID; GLYCOPROTEIN VI; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOSOME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNETIC NANOPARTICLE; MOLECULAR SCAFFOLD; NANOMATERIAL; NANOPARTICLE; OXIDIZED LOW DENSITY LIPOPROTEIN; PACLITAXEL; SMALL INTERFERING RNA; THROMBIN INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTERY THROMBOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BARE METAL STENT; BIOCOMPATIBILITY; BLOOD CLOT LYSIS; BLOOD CLOTTING; CHOLESTEROL TRANSPORT; CONSERVATIVE TREATMENT; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG RELEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FOAM CELL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; IN-STENT RESTENOSIS; INFLAMMATION; LIPID BLOOD LEVEL; MACROPHAGE; MOLECULAR PATHOLOGY; MONOCYTE; MUSCLE CELL; NANOMEDICINE; NANOTECHNOLOGY; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARGET CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOGENICITY; THROMBOSIS PREVENTION; TISSUE ENGINEERING; VASCULAR ENDOTHELIUM; VASCULAR PATENCY; VASCULITIS;

EID: 84873201194     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.08.009     Document Type: Review

References (40)

1. Blow N. Small RNAs: delivering the future. Nature 2007, 450:1117-1120.
2. Brito L., Amiji M. Nanoparticulate carriers for the treatment of coronary restenosis. International Journal of Nanomedicine 2007, 2:143-161.
3. Broz P., Ben-Haim N., Grzelakowski M., Marsch S., Meier W., Hunziker P. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin. Journal of Cardiovascular Pharmacology 2008, 51:246-252.
4. Cannon C.P., Steinberg B.A., Murphy S.A., Mega J.L., Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Journal of the American College of Cardiology 2006, 48:438-445.
5. Ceylan H., Tekinay A.B., Guler M.O. Selective adhesion and growth of vascular endothelial cells on bioactive peptide nanofiber functionalized stainless steel surface. Biomaterials 2011, 32:8797-8805.
6. Chan J.M., Rhee J.W., Drum C.L., Bronson R.T., Golomb G., Langer R., et al. In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:19347-19352.
7. Cho B.H., Park J.R., Nakamura M.T., Odintsov B.M., Wallig M.A., Chung B.H. Synthetic dimyristoylphosphatidylcholine liposomes assimilating into high-density lipoprotein promote regression of atherosclerotic lesions in cholesterol-fed rabbits. Experimental Biology and Medicine (Maywood) 2010, 235:1194-1203.
8. Chorny M., Fishbein I., Yellen B.B., Alferiev I.S., Bakay M., Ganta S., et al. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:8346-8351.
9. Danenberg H.D., Fishbein I., Gao J., Mönkkönen J., Reich R., Gati I., et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002, 106:599-605.
10. Danenberg H.D., Golomb G., Groothuis A., Gao J., Epstein H., Swaminathan R.V., et al. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 2003, 108:2798-2804.
11. Dangas G.D., Claessen B.E., Caixeta A., Sanidas E.A., Mintz G.S., Mehran R. In-stent restenosis in the drug-eluting stent era. Journal of the American College of Cardiology 2010, 56:1897-1907.
12. Farokhzad O.C., Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Advanced drug delivery reviews 2006, 58:1456-1459.
13. Hashi C.K., Zhu Y., Yang G.Y., Young W.L., Hsiao B.S., Wang K., et al. Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:11915-11920.
14. Joner M., Morimoto K., Kasukawa H., Steigerwald K., Merl S., Nakazawa G., et al. Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28:1960-1966.
15. Kipshidze N., Dangas G., Tsapenko M., Moses J., Leon M.B., Kutryk M., et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. Journal of the American College of Cardiology 2004, 44:733-739.
16. Kolodgie F.D., John M., Khurana C., Farb A., Wilson P.S., Acampado E., et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 2002, 106:1195-1198.
17. Kushwaha M., Anderson J.M., Bosworth C.A., Andukuri A., Minor W.P., Lancaster JR Jr., et al. A nitric oxide releasing, self assembled peptide amphiphile matrix that mimics native endothelium for coating implantable cardiovascular devices. Biomaterials 2010, 31:1502-1508.
18. Lan Hsia S., Duncan R., Schob A.H., Chakko S.C., Mulingtapang R., He J.L., et al. Serum levels of high-density lipoprotein phospholipids correlate inversely with severity of angiographically defined coronary artery disease. Atherosclerosis 2000, 152:469-473.
19. Lanza G.M., Yu X., Winter P.M., Abendschein D.R., Karukstis K.K., Scott M.J., et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002, 106:2842-2847.
20. Leuschner F., Dutta P., Gorbatov R., Novobrantseva T.I., Donahoe J.S., Courties G., et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nature Biotechnology 2011, 29:1005-1010.
21. Libby P., DiCarli M., Weissleder R. The vascular biology of atherosclerosis and imaging targets. Journal of Nuclear Medicine 2010, 51(Suppl. 1):33S-37S.
22. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
23. Lobatto M.E., Fayad Z.A., Silvera S., Vucic E., Calcagno C., Mani V., et al. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Molecular Pharmaceutics 2010, 7:2020-2029.
24. Margolis J., McDonald J., Heuser R., Klinke P., Waksman R., Virmani R., et al. Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-in-human safety and dose-finding study. Clinical Cardiology 2007, 30:165-170.
25. McCarthy J.R., Korngold E., Weissleder R., Jaffer F.A. A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small 2010, 6:2041-2049.
26. Moreno P.R., Purushothaman K.R., Fuster V., Echeverri D., Truszczynska H., Sharma S.K., et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004, 110:2032-2038.
27. Myerson J., He L., Lanza G., Tollefsen D., Wickline S. Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis. Journal of Thrombosis and Haemostasis 2011, 9:1292-1300.
28. Pendyala L.K., Matsumoto D., Shinke T., Iwasaki T., Sugimoto R., Hou D., et al. Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with Cypher stent. JACC: Cardiovascular Interventions 2012, 5:436-444.
29. Peters D., Kastantin M., Kotamraju V.R., Karmali P.P., Gujraty K., Tirrell M., et al. Targeting atherosclerosis by using modular, multifunctional micelles. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:9815-9819.
30. Polyak B., Fishbein I., Chorny M., Alferiev I., Williams D., Yellen B., et al. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:698-703.
31. Poon M., Gertz S.D., Fallon J.T., Wiegman P., Berman J.W., Sarembock I.J., et al. Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol fed rabbits. Atherosclerosis 2001, 155:371-380.
32. Rathore A., Cleary M., Naito Y., Rocco K., Breuer C. Development of tissue engineered vascular grafts and application of nanomedicine. Wiley interdisciplinary reviews. Nanomedicine and Nanobiotechnology 2012, 4:257-272.
33. Ross R. Atherosclerosis-an inflammatory disease. The New England Journal of Medicine 1999, 340:115-126.
34. Serruys P.W., Kutryk M.J., Ong A.T. Coronary-artery stents. The New England Journal of Medicine 2006, 354:483-495.
35. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. The New England Journal of Medicine 1995, 333:1301-1307.
36. Stankus J.J., Soletti L., Fujimoto K., Hong Y., Vorp D.A., Wagner W.R. Fabrication of cell microintegrated blood vessel constructs through electrohydrodynamic atomization. Biomaterials 2007, 28:2738-2746.
37. Stinchcombe T.E. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (London) 2007, 2:415-423.
38. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. The New England Journal of Medicine 2007, 356:998-1008.
39. Winter P.M., Caruthers S.D., Zhang H., Williams T.A., Wickline S.A., Lanza G.M. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC: Cardiovasc Imaging 2008, 1:624-634.
40. Winter P.M., Neubauer A.M., Caruthers S.D., Harris T.D., Robertson J.D., Williams T.A., et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2006, 26:2103-2109.